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A sequence about 40 amino acid residues long 
which has a significant homology to epidermal 
growth factor (EGF) has been found in many dif- 
ferent proteins in single or multiple copies. The 
homologies per se and available functional data 
suggest that these domains share some common 
functional features. 
One can consider the prototype sequence as that 
of EGF, a 53-residue peptide, which is derived 
from a much longer precursor containing nine 
other copies of EGF-like units. EGF causes 
pleiotropic proliferative and developmental effects 
which are mediated by a specific surface receptor 
endowed with tyrosine kinase activity [1,2]. Cer- 
tain shorter synthetic peptides compete with 
authentic EGF for receptor binding and mimic 
some of the functions of EGF, indicating that the 
minimal receptor binding sequence lies within 
residues 20-31 [3]; however, addition of the 
amino-flanking sequences dramatically improves 
its affinity for the receptor [4]. 
Several proteins which have significant sequence 
homology with EGF, or that contain one or more 
EGF-homologous repeats [e.g., urokinase (uPA), 
laminin Bl and low density lipoprotein receptor 
(LDL receptor)], are also involved in receptor- 
ligand interactions, and the sequences required for 
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their specific interactions have been identified. 
uPA catalyzes the proteolytic activation of inactive 
plasminogen to the broad spectrum serine pro- 
tease, plasmin. This reaction is regarded as crucial 
in regulating extracellular proteolysis, and hence in 
a variety of phenomena that require degradation 
of the extracellular matrix and of basement mem- 
brane 151. Some normal and neoplastic cells 
possess a specific uPA receptor which may serve 
the purpose of focusing the regulatory proteolytic 
activity of uPA on the cell-matrix contact sites [6]. 
Synthetic peptide studies show that the receptor 
binding specificity resides within residues 18-32 of 
uPA, i.e., within the EGF homologous domain. 
As in EGF, amino-flanking sequences (residues 
12-17) of uPA considerably increase the affinity 
for the receptor [7]. 
Laminin is a glycoprotein of the basement mem- 
brane that promotes the adhesion and growth of 
various epithelial normal and tumor cells [8]. 
Subunit Bl of laminin appears to be involved in 
binding to collagen and to a cell receptor. The se- 
quence of laminin Bl encodes several cysteine-rich 
repeats with homology to EGF 191 and some of 
these repeats are located in domain III which con- 
tains the portion of this protein required for cell 
binding. Synthetic peptide studies have shown that 
residues 925 to 933 of laminin in one of these 
repeats can mediate cell attachment, migration and 
receptor binding [lo]. 
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The LDL receptor is a cell surface protein that 
binds LDL, a plasma cholesterol binding protein, 
and carries it into the cell [ 111. The LDL receptor 
has three copies of a disulfide-bonded, cysteine- 
rich repeat of approx. 40 amino acid residues hav- 
ing homology to EGF. Analysis of the structure of 
the LDL-receptor gene in subjects with familial 
hypercholesterolemia has shown that deletion of 
exons 7 and 8 (i.e., the first two copies of the EGF- 
homologous repeat) strongly interferes with the 
binding capacity and specificity of this receptor 
t121. 
Many other proteins contain regions of 
homology to EGF, and cysteine residues at similar 
positions (fig. 1). They include tissue plasminogen 
activator (tPA), coagulation factors VII (with two 
domains), IX, X and XII (with two domains), pro- 
tein C, protein S and protein Z, the Drosophila 
NOTCH sequence, the C. elegans LIN sequence, 
transforming growth factor+ and the EGF precur- 
sor, which contains other EGF-like sequences in 
addition to EGF. Thus, all the proteins listed 
above (see also fig.1) are known, or may be ex- 
pected to participate in protein-protein or protein- 
cell interactions. They are growth factors, recep- 
tors, or receptor-like proteins or proteins of the 
coagulation and fibrinolytic pathway, suggesting 
that the EGF-like regions are responsible for the 
interactions with a receptor or a ligand. 
In order to gain further insight into the struc- 
tural characteristics of the EGF-like region, the se- 
quence homologies in. these regions of the above 
proteins (fig.1) must be re-evaluated. The 
homologies can be grouped into three different 
categories. In fig. 1, we have numbered the cysteine 
residues as Cysl-Cys6, following the order in 
which they appear in uPA, with Cysl the closest to 
the N-terminus. We note that five of the six cys- 
teine residues, which correspond to positions 
Cys2-Cys6 of uPA, align very well among the dif- 
ferent proteins, but that the Cysl residue does not. 
In some proteins the extra cysteine residue is N- 
terminal to Cys2 (as in EGF, uPA and others), but 
in other cases (as in the LDL receptor) it is present 
between Cys3 and Cys4 (see below). We want to 
emphasize that, so far, the actual disulfide bon- 
ding has been determined only for EGF and TGF- 
LY (i.e., Cysl with Cys3, CyQ with Cys4 and Cys5 
with Cyd) [13,14]-. 
We have grouped the sequences homologous to 
2 
Fig. 1. Sequence homology among proteins haring an EGF-like 
region. Symbols follow the one-letter code. A minus sign 
indicates a gap introduced for sequence alignment; a dot 
indicates identity to the first sequence, human urokinase (h 
uPA). The conserved cysteines are numbered 1 to 6, and the 
disulfide bonds are expected to form as shown: Cysl3, Cys2-4, 
CysS-6. Sequences have been obtained as follows: h uPA [18]; 
human tissue plasminogen activator (h tPA) [19]; human 
epidermal growth factor (h-EGF) and seven repeats of the 
human EGF precursor (h EGF Prr.7) [2O]; human transforming 
growth factor* (h TGF-cr) [21]; vuccinia virus 19 kDa protein 
(Va 19K) [22]; mouse laminin Bl (m LaminBr) [9]; the 9th 
repeat of the C. elegutrs partial sequence of Linl2 (Linrz, 9th) 
[23]; human coagulation factor VII, 1st and 2nd repeat (h VII, 
and h VIIr) [24]; human coagulation factor IX (h IX) [25]; 
human coagulation factor X (h X) [26]; 1st and 2nd repeat of 
human coagulation factor XII (h XII1 and h X112) 1271; bovine 
protein S (b prS) [28]; human protein C (h prC) [29]; bovine 
protein Z (b prZ) [30]; Drosophila melanogaster NOTCH gene 
cysteine-rich repeat consensus sequence (d NOTCH& [31]; 
human LDL-receptor exons 7 and 8 (h LDL-R exon7, h LDL-R 
exon8) [ 121. 
EGF as follows: in type 1 sequences (uPA, tPA, 
EGF, TGF-(r, 19 kDa protein), the position of 
Cysl is N-terminal to Cys2, with l-7 residues be- 
tween Cysl and Cys2. The regularity in cysteine 
Volume 23 1, number 1 FEBS LETTERS April 1988 
spacing identifies three regions, A, B and C. 
Region A (Cys2-Cys3) is highly conserved in 
length (5-6 residues) and sequence. Region B 
(Cys3-Cys4) contains between 10 and 11 residues 
and is highly divergent in sequence (except in the 
closely related uPA and tPA). Region C (between 
CysS and Cys6) is conserved in length and has 4-5 
specific residues. In the sequence of laminin Bl, 
the Cys2 residue is missing. It is possible that a cys- 
teine lying outside this region forms a disulfide 
bond with Cys4. 
In type 2 sequences (coagulation factors VIII, 
IX, X, X111,2,, protein S, protein C, protein Z, 
the Drosophila ‘NOTCH’ sequence), region A has 
the same properties as in type 1 sequences; and 
Cysl is located N-terminal to Cys2 with variable 
separation. Also region C has features similar to 
those of type 1 sequences. Region B, however, is 
consistently three residues shorter than in type 1 se- 
quences and has more conserved residues. 
Type 3 sequences (LDL receptor, coagulation 
factor VII11, various units of the EGF precursor) 
differ in several respects from the other two. 
Region A is less conserved in length and sequence. 
Region B is interrupted by Cysl . The three regions 
are less conserved in spacing but still contain many 
identifiable sequence identities with respect to each 
other or to type 1 and type 2. It is not clear whether 
a Cysl to Cyb disulfide bond forms in type 3 se- 
quences, and therefore the structure may be quite 
different. 
The comparisons in fig.1 show that consensus 
sequences can be generated in the three groups of 
proteins. Thus homology is not limited to the cys- 
teine residues but also includes the conservation of 
other amino acids. Regions A and C are well con- 
served even in type 3 sequences (allowing for the 
various insertions). Region B is quite variable in 
type 1 sequences, but is more conserved in the 
other two groups. 
The secondary structure of residues 1-48 of 
human EGF in solution has been recently deter- 
mined by NMR measurements [ 151. On the basis of 
that study, and assuming that the disulfide 
bonding is conserved in the EGF-like region of 
other proteins, a common three-dimensional struc- 
ture can be predicted (fig.2). The three disulfide 
bonds constrain the structure to fold into four 
loops which correspond to the variable length 
region between Cysl and Cys2, and the regions A, 
loop A 
loop B 
Fig.2. Predicted structure of type 1 EGF-like domains. A
schematic drawing of the common structure predicted for the 
EGF-like domains based on the solution structure of human 
EGF (residues l-48) reported by Cooke et al. [15]. The open 
circles represent amino acid residues. Cysl-Cyd are numbered 
and the three disulfide bridges indicated. Loops A, B and C are 
conserved in length, while the loop between Cysl and Cys2 (in 
dashed lines) is variable in length. Loop B consists of two & 
strands and forms the recognition sequence. The type 2 EGF 
domain is predicted to have a similar structure, except that loop 
B is three residues shorter. 
B and C shown in fig.2. This common structure 
consists of two antiparallel @-strands between Cys3 
and Cys4 (loop B). The other loops have less 
regular secondary structure, although loop C con- 
tains two turns. This analysis suggests that several 
of the conserved residues are important for form- 
ing turns in the structure. In general, there is a con- 
served proline after Cysl and proline or glycine 
just before Cys2. Loop A has a conserved pair of 
glycines in the middle, and loop C has two 
glycines, one in each of the two turns. Loop B, 
despite the well-defined secondary structure, does 
not contain conserved turn-forming residues, most 
likely be&use this loop forms the recognition site. 
Type 1 and type 2 EGF homologous regions are 
predicted to fold as shown in fig.2; type 3, 
however, is expected to form different structures 
since the Cysl and Cys3 disulfide, if present, 
3 
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would be in different positions relative to type 1 
and type 2 sequences. In the case of the type 1 se- 
quences, the available data suggest hat loop B is 
the binding site. In the case of type 2 sequences, 
however, since the degree of conservation is quite 
high in all three loops, it would be likely that addi- 
tional sequences (not included in fig.1) determine 
or contribute to the binding site and/or specificity. 
Recent data support this prediction. Coagulation 
factor IX has been shown to have specific recep- 
tors on the surfaces of endothelial cells [16]. Short 
synthetic peptides derived from the sequence of the 
first EGF-like region (involving residues 47-54 
just before the EGF-like regions of fig. 1) function 
as competitive inhibitors of the factor IX- 
endothelial cell interaction [ 171. 
The above analysis predicts: (i) that the EGF- 
like regions of various proteins are involved in 
receptor-ligand interactions; (ii) that a common 
structural folding is shared by the EGF-like do- 
mains, based on the sequence homologies and dic- 
tated by the position of the three disulfide bonds; 
(iii) that in type 1 sequences this common structure 
forms three loops which together provide specifici- 
ty and maximum binding affinity - in these pro- 
teins, according to the data available on EGF and 
uPA, the recognition sequence is located in loop B, 
but the combination of more than one loop is 
probably required for maximum affinity; and (iv) 
that specific receptors have co-evolved with the 
above EGF-like structures. 
For EGF, the receptor has been shown to be a 
membrane-spanning protein with an outer, EGF- 
binding domain. The EGF-like regions of the other 
proteins might define various classes of receptors 
or ligands sharing a common secondary structure, 
at least in the region involved in receptor-ligand in- 
teraction. 
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